SG10201607410TA - Human binding molecules capable of neutralizing influenza virus h5n1 and uses thereof - Google Patents
Human binding molecules capable of neutralizing influenza virus h5n1 and uses thereofInfo
- Publication number
- SG10201607410TA SG10201607410TA SG10201607410TA SG10201607410TA SG10201607410TA SG 10201607410T A SG10201607410T A SG 10201607410TA SG 10201607410T A SG10201607410T A SG 10201607410TA SG 10201607410T A SG10201607410T A SG 10201607410TA SG 10201607410T A SG10201607410T A SG 10201607410TA
- Authority
- SG
- Singapore
- Prior art keywords
- influenza virus
- binding molecules
- molecules capable
- human binding
- neutralizing influenza
- Prior art date
Links
- 230000003472 neutralizing effect Effects 0.000 title 1
- 241000712461 unidentified influenza virus Species 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1018—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Pulmonology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Communicable Diseases (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US84293006P | 2006-09-07 | 2006-09-07 | |
| EP06120316 | 2006-09-07 | ||
| EP06120644 | 2006-09-14 | ||
| EP06125107 | 2006-11-30 | ||
| EP07111235 | 2007-06-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201607410TA true SG10201607410TA (en) | 2016-10-28 |
Family
ID=45468077
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG2011063955A SG174773A1 (en) | 2006-09-07 | 2007-09-06 | Human binding molecules capable of neutralizing influenza virus h5n1 and uses thereof |
| SG10201607410TA SG10201607410TA (en) | 2006-09-07 | 2007-09-06 | Human binding molecules capable of neutralizing influenza virus h5n1 and uses thereof |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG2011063955A SG174773A1 (en) | 2006-09-07 | 2007-09-06 | Human binding molecules capable of neutralizing influenza virus h5n1 and uses thereof |
Country Status (11)
| Country | Link |
|---|---|
| EP (5) | EP2450376B1 (da) |
| BR (1) | BRPI0716983B8 (da) |
| DK (5) | DK2455398T3 (da) |
| ES (1) | ES2402217T3 (da) |
| MX (1) | MX343198B (da) |
| MY (1) | MY165458A (da) |
| NZ (1) | NZ574581A (da) |
| PT (1) | PT2059532E (da) |
| RS (1) | RS52688B (da) |
| SG (2) | SG174773A1 (da) |
| SI (1) | SI2059532T1 (da) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110028578B (zh) * | 2019-03-12 | 2021-05-11 | 中国科学院武汉病毒研究所 | 广谱抗h7流感病毒的中和性人源单克隆抗体及其应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4625015A (en) * | 1982-08-23 | 1986-11-25 | Scripps Clinic & Research Foundation | Broad spectrum influenza antisera |
| NZ207394A (en) | 1983-03-08 | 1987-03-06 | Commw Serum Lab Commission | Detecting or determining sequence of amino acids |
| NL9101953A (nl) | 1991-11-21 | 1993-06-16 | Seed Capital Investments | Testinrichting omvattende een plaat met een veelvoud van putjes met een bijbehorende doseerinrichting, alsmede een kit die deze inrichtingen omvat en toepassing van de inrichtingen. |
| US5589174A (en) * | 1992-09-17 | 1996-12-31 | Takara Shuzo Co., Ltd. | Anti-human influenza virus antibody |
| US5624949A (en) | 1993-12-07 | 1997-04-29 | Eli Lilly And Company | Protein kinase C inhibitors |
| US6265150B1 (en) | 1995-06-07 | 2001-07-24 | Becton Dickinson & Company | Phage antibodies |
| JP2001512560A (ja) | 1996-10-08 | 2001-08-21 | ユー―ビスイス ベスローテン フェンノートシャップ | 標的に対し特異的な親和性を有するペプチドおよびタンパク質の選択のための方法および手段 |
| ATE536417T1 (de) | 1999-04-15 | 2011-12-15 | Crucell Holland Bv | Herstellung von rekombinanten proteinen in einer menschlichen zelle mit mindestens einem e1 adenovirus protein |
| US7521220B2 (en) | 1999-11-26 | 2009-04-21 | Crucell Holland B.V. | Production of vaccines |
| CA2449071C (en) | 2001-06-15 | 2008-12-16 | Crucell Holland B.V. | Chimaeric phages |
-
2007
- 2007-09-06 PT PT78033107T patent/PT2059532E/pt unknown
- 2007-09-06 ES ES07803310T patent/ES2402217T3/es active Active
- 2007-09-06 RS RS20130086A patent/RS52688B/en unknown
- 2007-09-06 SI SI200731176T patent/SI2059532T1/sl unknown
- 2007-09-06 DK DK12153015.8T patent/DK2455398T3/da active
- 2007-09-06 SG SG2011063955A patent/SG174773A1/en unknown
- 2007-09-06 DK DK12153016.6T patent/DK2455399T3/da active
- 2007-09-06 DK DK12153012.5T patent/DK2450378T3/da active
- 2007-09-06 NZ NZ574581A patent/NZ574581A/en not_active IP Right Cessation
- 2007-09-06 EP EP12153009.1A patent/EP2450376B1/en active Active
- 2007-09-06 MY MYPI20090915A patent/MY165458A/en unknown
- 2007-09-06 EP EP12153016.6A patent/EP2455399B1/en active Active
- 2007-09-06 SG SG10201607410TA patent/SG10201607410TA/en unknown
- 2007-09-06 DK DK12153013.3T patent/DK2450379T3/da active
- 2007-09-06 MX MX2013010235A patent/MX343198B/es unknown
- 2007-09-06 EP EP12153012.5A patent/EP2450378B1/en active Active
- 2007-09-06 BR BRPI0716983A patent/BRPI0716983B8/pt not_active IP Right Cessation
- 2007-09-06 EP EP12153015.8A patent/EP2455398B1/en active Active
- 2007-09-06 EP EP12153013.3A patent/EP2450379B1/en active Active
- 2007-09-06 DK DK07803310.7T patent/DK2059532T3/da active
Also Published As
| Publication number | Publication date |
|---|---|
| EP2455398A3 (en) | 2012-05-30 |
| EP2450376B1 (en) | 2018-02-28 |
| EP2450378B1 (en) | 2015-11-04 |
| DK2455399T3 (da) | 2016-01-25 |
| SG174773A1 (en) | 2011-10-28 |
| EP2455399B1 (en) | 2015-11-04 |
| DK2455398T3 (da) | 2016-02-08 |
| BRPI0716983B8 (pt) | 2021-05-25 |
| EP2450376A3 (en) | 2012-08-01 |
| NZ574581A (en) | 2012-02-24 |
| DK2450379T3 (da) | 2016-02-08 |
| BRPI0716983A2 (pt) | 2013-10-15 |
| EP2450376A2 (en) | 2012-05-09 |
| EP2455398A2 (en) | 2012-05-23 |
| MY165458A (en) | 2018-03-22 |
| EP2450379B1 (en) | 2015-11-04 |
| DK2059532T3 (da) | 2013-03-18 |
| SI2059532T1 (sl) | 2013-04-30 |
| EP2450378A1 (en) | 2012-05-09 |
| BRPI0716983B1 (pt) | 2019-03-26 |
| EP2455398B1 (en) | 2015-11-18 |
| PT2059532E (pt) | 2013-03-07 |
| EP2455399A2 (en) | 2012-05-23 |
| ES2402217T3 (es) | 2013-04-29 |
| RS52688B (en) | 2013-08-30 |
| EP2455399A3 (en) | 2012-05-30 |
| EP2450379A1 (en) | 2012-05-09 |
| DK2450378T3 (da) | 2016-02-01 |
| MX343198B (es) | 2016-10-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL249291A0 (en) | Human binding molecules capable of neutralizing H5N1 influenza virus and their uses | |
| KR101790354B9 (ko) | 인플루엔자 바이러스 ｈ3ｎ2를 중화시킬 수 있는 인간 결합 분자 및 그것의 용도 | |
| ZA201004478B (en) | Antibodies against influenza virus and methods of use thereof | |
| EP1993611A4 (en) | RNAi MODULATION OF TGF-BETA AND THERAPEUTIC USES | |
| IL239023A0 (en) | Neutralizing antibodies to influenza virus | |
| ZA201104495B (en) | Conjugates of neurotensin or neurotensin analogs and uses thereof | |
| ZA201101150B (en) | Neutralizing anti-influenza a virus antibodies and uses thereof | |
| EP2010210A4 (en) | VACCINE AGAINST BIRD FLUID AND METHOD OF APPLICATION THEREFOR | |
| PL2589602T3 (pl) | Rozwinięcie komponentów szczepionki przeciwko wirusowi dengi | |
| EP2136846A4 (en) | THERAPEUTIC OBJECTIVES AND MOLECULES | |
| ZA200908100B (en) | Treatment and prevention of influenza | |
| IL197501A0 (en) | Modifications of cupredoxin derived peptides and methods of use thereof | |
| EP2277891A4 (en) | CRYSTAL STRUCTURE OF THE POLYMERASE PAC-PB1N COMPLEX OF THE FLUID VIRUS AND USES THEREOF | |
| ZA201000225B (en) | Treatment of depression | |
| EP2184353A4 (en) | TREATMENT OF INFLUENZA | |
| PL2084272T3 (pl) | Klonowanie, ekspresja oraz zastosowanie kwaśnych lizofosfolipaz | |
| SG10201607410TA (en) | Human binding molecules capable of neutralizing influenza virus h5n1 and uses thereof | |
| EP2043428A4 (en) | MODULATORS OF RNF5 AND USES THEREOF | |
| SI1749029T1 (sl) | Vezavne molekule, sposobne nevtraliziranja virusa stekline, in njihove uporabe | |
| GB0605333D0 (en) | Treatment of influenza | |
| AU2007902616A0 (en) | Treatment and prevention of influenza | |
| GB0704989D0 (en) | Treatment of influenza | |
| AU2007319715A8 (en) | Vaccine for avian influenza and methods of use | |
| GB0505491D0 (en) | Treatment of influenza | |
| GB0615014D0 (en) | Methylamine risks and treatment of hyper-activity, depression, drug dependences and alcoholism |